Viveve Medical, Inc. (VIVE): BCG Matrix [Dec-2025 Updated]

You're looking at the final chapter for Viveve Medical, Inc., and mapping its remnants onto the classic BCG Matrix reveals a stark picture as of late 2025. Forget high-growth Stars or reliable Cash Cows; the operating business is gone, following the late 2023 bankruptcy and asset sale. What remains is the ultimate Dog-a residual corporate shell trading on the OTC market with a market capitalization barely above $1.08 thousand in November 2025-while its former core technology shines as a Star for its acquirer. Dive in to see how the former flagship product and the stock ticker itself fit into this post-liquidation portfolio analysis.

Background of Viveve Medical, Inc. (VIVE)

You're looking at the history of Viveve Medical, Inc., a company that, until recently, was focused on developing and marketing medical devices for women's intimate health. Founded in 2005, Viveve Medical, Inc. was headquartered in Englewood, Colorado, and operated within the Medical Devices industry. Its primary offering was the Viveve System, which used patented Cryogen-cooled Monopolar Radiofrequency (CMRF) technology. This system was designed for the non-invasive treatment of conditions like vaginal introital laxity, sexual function issues, vaginal rejuvenation, and stress urinary incontinence (SUI).

The revenue stream for Viveve Medical was built on selling the radiofrequency generator, reusable handpiece, and treatment tips, along with recurring consumable components like cryogen canisters. For context on its last full period of independent operation, the trailing twelve-month revenue as of late 2022 stood at approximately $6.83M, up from $6.43M in the 2021 fiscal year. The company marketed its products globally through a mix of direct sales employees and distributors across the US, Canada, Europe, and Asia Pacific.

However, the company faced significant challenges that defined its later history. A major turning point was the disappointing results from its pivotal U.S. PURSUIT clinical trial for treating SUI, where the primary efficacy endpoint was not achieved. Following these results, Viveve Medical announced workforce reductions and stated it would seek strategic alternatives, which ultimately culminated in bankruptcy proceedings and an asset sale around 2023-2024. As a result, Viveve Medical ceased independent operations, with its technology and intellectual property now under new ownership.

As of December 4, 2025, the ticker VIVE reflected this final state, with the stock concluding trading at a price of $0.0001 and a reported market capitalization of just $4.29K. Analysts noted that while the total addressable market for these therapies remains large, skeptical views questioned whether the entity, in its final form, could capture that expansion. The company's equity performance was being tracked relative to benchmarks even as trading concluded for the entity under this ticker.

Viveve Medical, Inc. (VIVE) - BCG Matrix: Stars

As of November 2025, Viveve Medical, Inc. is not an operating entity capable of having Stars in its portfolio. Following a Chapter 11 bankruptcy filing in late 2023, the company's key assets were acquired by InMode Ltd. in early 2024, leading to its current status of Chapter 7 liquidation. Consequently, the operational revenue for Viveve Medical, Inc. in the 2025 fiscal year is effectively $0 (zero).

The last reported Trailing Twelve Months (TTM) revenue for the former Viveve Medical, Inc., prior to the operational wind-down, was $6.82 Million USD. This historical context contrasts sharply with the current reality of the ticker VIVE, which reflects a complete business failure and liquidation, with a market capitalization of approximately $4.29K as of November 2025.

The core technology, the Cryogen-cooled Monopolar Radiofrequency (CMRF) technology, which powered the Viveve System, is now positioned as a Star, but this classification applies to the acquirer, InMode Ltd., as it operates in a high-growth market with the potential for high market share capture with the acquired intellectual property. Stars are defined by having high market share in a growing market.

InMode Ltd., the owner of the CMRF IP, is actively investing in growth, which is the key tenet of a Boston Consulting Group (BCG) strategy for Stars. For context on the acquirer's scale, InMode Ltd. reported Third Quarter 2025 revenue of $93.2 Million and reiterated full-year 2025 guidance between $365 Million and $375 Million.

Viveve Medical, Inc. has no high-growth, high-market-share product generating significant revenue in 2025. The technology's potential is now realized under InMode Ltd.'s umbrella, which has a much stronger financial footing, evidenced by its total cash position of $512.9 million as of March 31, 2025.

Here is a comparison of the relevant financial scale, showing why the technology is now a Star for the acquirer, not the former entity:

The CMRF technology, now under InMode Ltd., fits the Star profile because it is a leader in a market segment that analysts see as rapidly expanding. The broader energy-based aesthetic devices market is estimated to be valued at $20.62 Billion USD in 2025.

The characteristics defining the CMRF technology as a Star for InMode Ltd. include:

• Technology is a leader in the women's health device space.
• It is now supported by InMode Ltd.'s financial strength.
• The market for related therapies is expanding rapidly.
• It requires significant investment for promotion and placement.
• It has the potential to become a Cash Cow if market growth slows.

Stars consume large amounts of cash due to their high growth rate, often resulting in cash flow that is nearly break-even, which is why InMode Ltd. must invest heavily to maintain its market share gains. If the market share is kept, Stars are likely to grow into cash cows when the high-growth market slows down.

For you, the key takeaway is that the asset itself is valuable and growing within a new structure. Finance: draft the integration cost analysis for the acquired CMRF IP by next Tuesday.

Viveve Medical, Inc. (VIVE) - BCG Matrix: Cash Cows

You're looking at the remnants of a business, and in the context of the Boston Consulting Group Matrix, the Cash Cow quadrant is entirely empty for Viveve Medical, Inc. as of 2025. This is a direct consequence of the corporate structure's collapse, not a strategic choice regarding product maturity.

Zero operating business units are generating positive cash flow or high relative market share. The core technology, the Viveve System, is now under the ownership of InMode Ltd. following an asset acquisition in early 2024. This means Viveve Medical, Inc. itself has no active products contributing to its bottom line.

The company is not a going concern, so there are no products to fund other ventures. The entity is in the process of a Chapter 7 liquidation. Trading activity concluded on December 4, 2025, with a market capitalization of approximately $4.29K as of November 2025.

The last reported Trailing Twelve Months (TTM) revenue before wind-down was only $6.82 million, which was not a cash-cow level. A true Cash Cow generates substantial, stable cash flow that significantly exceeds its minimal investment needs. The financial metrics leading up to the wind-down clearly show this was not the case.

Here's a look at the pre-liquidation financial reality that prevented any product from qualifying as a Cash Cow:

The concept of a Cash Cow requires high market share in a mature market, leading to high profit margins and strong cash flow. For Viveve Medical, Inc., the historical performance shows the opposite trend, making the Cash Cow quadrant an empty placeholder.

• Zero business units meet the high market share criteria.
• The company ceased independent operations in early 2024.
• Cash flow from operations was negative, not positive.
• The last reported TTM revenue was $6.82 Million USD.
• The entity is currently in Chapter 7 liquidation status.

Investments into supporting infrastructure, which Cash Cows typically use for efficiency gains, were irrelevant as the company was burning capital. The last reported figures confirm the lack of positive cash generation.

Finance: draft the final Chapter 7 asset distribution report by Monday.

Viveve Medical, Inc. (VIVE) - BCG Matrix: Dogs

You're looking at the remnants of a business unit that, in this case, represents the entire residual corporate entity, VIVE. In the Boston Consulting Group framework, this is the ultimate Dog in the portfolio, characterized by low market share and low growth, which is now effectively a non-operating shell following major corporate events.

The current financial footprint reflects this status. As of late 2025, the common stock (VIVE) trades on the OTC market, a venue often associated with highly distressed or non-reporting entities. The market capitalization reflects this near-zero value proposition.

The former flagship product, the Viveve® System, which utilized patented cryogen-cooled monopolar radiofrequency (CMRF) technology, held a negligible market share, estimated at <1% in the broader aesthetic device market before the asset sale. This low share confirms its Dog status even before the operational collapse.

The primary catalyst for this positioning was the failure of the pivotal growth driver. Here are the key data points from that event:

• Failed pivotal trial for Stress Urinary Incontinence (SUI) in 2023.
• The U.S. PURSUIT study did not meet its primary efficacy endpoint at 12 months post-treatment.
• Active treatment group achieved a 49.8% reduction in leakage versus 56.7% in the sham group.
• The $p$-value for the primary endpoint comparison was 0.2035.
• The company announced it would not pursue FDA registration for the SUI indication.

To be fair, the company's core business operations effectively ceased following a Chapter 11 bankruptcy filing in late 2023. This event confirms the market's low growth expectation and the strategic decision to avoid further investment in this unit, as expensive turn-around plans rarely work when the fundamental growth engine stalls.

The company's financial position leading up to the collapse showed significant strain, even before the final trial results were known. For instance, as of December 2, 2020, the company reported a \$6.83 million revenue over the last 12 months against -\$28.14 million in losses. The current structure is a candidate for divestiture, as the cash tied up in the residual entity brings back almost nothing in return.

Viveve Medical, Inc. (VIVE) - BCG Matrix: Question Marks

You're looking at the remnants of a business, which in BCG terms, is the textbook definition of a Question Mark that has failed to transition to a Star. The VIVE stock ticker itself represents this residual value for a shell entity, trading at a price of $0.0001100 as of December 4, 2025. This is a market capitalization of approximately $4.29K as of November 2025, a clear indicator that the operating business has ceased to exist.

Any potential recovery for equity holders is highly uncertain, given the common equity is essentially worthless following the Chapter 7 liquidation process initiated after the Chapter 11 filing in late 2023. The core assets, specifically the Viveve System technology and all worldwide patents, were acquired by InMode Ltd. on July 25, 2023. This transaction essentially stripped the operating value from the entity that now trades under VIVE.

Residual non-core assets or potential proceeds from the liquidation process are the only remaining question marks. These elements consume cash through administrative costs but offer negligible returns, fitting the Question Mark profile of high demand for resolution but low current return. The company's last reported Trailing Twelve Month (TTM) revenue before this operational wind-down was $6.82 Million USD. Compare that to the current trading status, and you see the magnitude of the cash burn and value destruction.

Future litigation outcomes or residual intellectual property not acquired by InMode Ltd. are the only high-risk, low-share elements left. The strategy here is not about market adoption anymore; it's about the final accounting of the shell. We must monitor the Chapter 7 trustee's final reports for any distributions, however small, to the remaining equity holders.

Here's a quick look at the historical financial context versus the current shell status, which helps frame the magnitude of the Question Mark:

The elements that define this Question Mark quadrant for Viveve Medical, Inc. are entirely centered on the wind-down process, not product growth. You need to track these specific, low-probability outcomes:

• The final distribution percentage to unsecured creditors.
• Any residual, non-patent-related intellectual property value.
• The final administrative costs of the Chapter 7 proceeding.
• The outcome of any remaining, unassigned legal claims.
• The total number of shares outstanding for final calculation purposes, which was 10,670 K historically.

To be fair, the company's historical structure was a razor-and-blade model, selling the console and then the single-use treatment tips. That model required significant investment to gain market share, which it failed to secure before running out of capital. The growth prospects are now zero, meaning the decision to invest heavily or sell has already been made by the bankruptcy court and InMode Ltd.

Finance: confirm the latest filing date for the Chapter 7 trustee's report by next Tuesday.